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Abstract: Inhibition of AB5-type bacterial toxins can be achieved by heterobifunctional 
ligands (BAITs) that mediate assembly of supramolecular complexes involving the toxin’s 
pentameric cell membrane-binding subunit and an endogenous protein, serum amyloid P 
component, of the innate immune system. Effective in vivo protection from Shiga toxin 
Type  1  (Stx1)  is  achieved  by  polymer-bound,  heterobifunctional  inhibitors-adaptors 
(PolyBAITs), which exhibit prolonged half-life in circulation and by mediating formation 
of face-to-face SAP-AB5 complexes, block receptor recognition sites and redirect toxins to 
the spleen and liver for degradation. Direct correlation between solid-phase activity and 
protective dose of PolyBAITs both in the cytotoxicity assay and in vivo indicate that the 
mechanism of protection from intoxication is inhibition of toxin binding to the host cell 
membrane. The polymeric scaffold influences the activity not only by clustering active 
binding  fragments  but  also  by  sterically  interfering  with  the  supramolecular  complex 
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assembly. Thus, inhibitors based on N-(2-hydroxypropyl) methacrylamide (HPMA) show 
significantly  lower  activity  than  polyacrylamide-based  analogs.  The  detrimental  steric 
effect can partially be alleviated by extending the length of the spacer, which separates 
pendant  ligand  from  the  backbone,  as  well  as  extending  the  spacer,  which  spans  the 
distance between binding moieties within each heterobifunctional ligand. Herein we report 
that  polymer  size  and  payload  of  the  active  ligand  had  moderate  effects  on  the  
inhibitor’s activity. 
Keywords: E. coli O157:H7; multivalent inhibitors; P
k-trisaccharide; Gb3 
 
1. Introduction 
Enteric infections with Shigatoxigenic Escherichia coli (STEC), particularly the O157:H7 strain, is 
the leading cause of hemolytic-uremic syndrome (HUS) in industrialized countries [1]. HUS is a term 
for an acute form of renal disease that commonly manifests itself as hemolytic anemia, acute renal 
failure,  thrombocytopenia,  and  central  nervous  system  impairment.  Most  symptoms  of  HUS  are 
mediated by exotoxins called Shiga toxins (Stx) that enter the circulation through an eroded intestinal 
epithelium and are rapidly absorbed in target tissues such as the kidney and the central nervous system, 
as well as inflicting serious systemic damage [2].  
Shiga toxins are a group of closely related bacterial toxins that are serologically differentiated into 
two types, Stx1 and Stx2 with ~60% homology, and a number of variants differing by just a few amino 
acids. Stx are potent cytotoxins with ribosomal deadenylase activity that cause cell death through 
activating pro-apoptotic signals by inducing an endoplasmic reticulum stress response in susceptible 
tissues. The Stx host cell receptor is the P
k trisaccharide head group [Gal(ʱ1-4)Gal(β1-4)Glc(β1-O)] of 
the glycolipid, Gb3.  
Since outbreaks of STEC infections can be contained by sanitary measures and by monitoring the 
water and food supply the incidence of HUS is relatively low, hence, immunization of the general 
population cannot be justified given the safety constraints of a vaccine. Treatment of infected patients 
is needed to prevent progression of the infection to HUS. However, despite tremendous advances in 
understanding  STEC  pathogenesis  the  clinical  options  for  treatment  remain  limited  to  mainly 
supportive strategies. Antibiotics can stimulate further Stx production and, therefore, are presently not 
recommended  [3,4].  Most  notable,  an  earlier  attempt  to  develop  a  Stx-targeting  therapy  for  
STEC-induced HUS was an orally administered indigestible affinity agent, Synsorb-P
k, designed to 
sequester Stx in the intestine before Stx entered the circulation. Unfortunately, this approach failed to 
demonstrate significant efficacy in a Phase 2 clinical trial [5]. Recently, passive immunization with 
monoclonal antibodies raised against Stx1 [6] and Stx2 [7] has been shown to be effective in animal 
models and a humanized monoclonal antibody urtoxazumab against Shiga-like toxin 2 is undergoing 
clinical trials [8]. Compounds that affect intracellular trafficking of Stx have shown efficacy in vitro 
and in vivo [9,10]. This suggests that a soluble injectable antitoxin agent might be able to prevent or 
lessen the severity of HUS.  Toxins 2011, 3                         
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Recently,  we  demonstrated  the  in  vivo  efficacy  of  a  polyacrylamide-based  pre-ordered 
heterobifunctional  ligand  named  PolyBAIT  that  induces  the  formation  of  face-to-face  complexes 
between the Shiga toxin pentameric B-subunit (Stx1-B5) and an endogenous human serum protein, 
serum amyloid P component (SAP, Figure 1), thereby protecting mice from intoxication by Stx1 [11]. 
SAP  is  a  serum  circulating  pentraxin,  a  pentameric  doughnut-shaped  protein,  that  topologically 
matches the pentameric carbohydrate binding subunit of Stx1. The ligand-mediated ternary complex 
formation with SAP inhibits the cell-recognition domain of Stx1 and facilitates safe disposal of the 
complex in the liver [11]. 
Figure 1. Molecular model of supramolecular complexes between Stx1 and SAP mediated 
by PolyBAIT. SAP: Green surface; Stx1-B5 subunit: Blue surface; Stx1-A subunit: Pink 
surface. Left panel: PolyBAIT with fused binding fragments; Right panel: PolyBAIT with 
separate binding fragments. Polymer atoms omitted for clarity. Molecular representation 
was rendered with PyMol (www.pymol.org). 
 
Herein we report the synthesis and activity evaluation of a series of glycoconjugates containing a 
ligand with dual specificity for Stx1 and SAP linked to the polymeric scaffolds, polyacrylamide and  
N-(2-hydroxypropyl) methacrylamide (HPMA). We employ narrow molecular weight range polymeric 
scaffolds  obtained  by  RAFT  polymerization  in  order  to  investigate  the  impact  of  the  nature  and 
the size  of  the  polymeric  backbone  and  the  linker  on  the  activities  of  the  polymeric  
heterobifunctional ligands.  Toxins 2011, 3                         
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2. Materials and Methods 
2.1. Synthesis of Heterobifunctional Inhibitors 
Commercially available reagents were used as supplied without further purification. Evaporation 
and concentration in vacuo was conducted under water-aspirator pressure. All solution-phase reactions 
were  carried  out  under  nitrogen  atmosphere.  Reactions  were  monitored  by  analytical  thin-layer 
chromatography (TLC) with pre-coated silica gel 60 F254 glass plate (Merck). Plates were visualized 
under  UV  light  or  stained  by  treatment  with  either  cerium  ammonium  molybdate  solution  or 5% 
sulfuric acid in ethanol followed by heating at 180 ° C. Purification of products was conducted by 
column chromatography using silica gel SiliaFlashF60 (40–63 μm, 60 Å) from SiliCycle
® Inc. IR data 
were recorded on a Nic–Plan IR Microscope (solid film); only signals corresponding to functional 
groups indicative to the structure are reported. NMR spectra were recorded at 500 or 600 MHz, at  
27 ° C in CDCl3 or D2O. Chemical shifts are referenced to residual solvent (CDCl3) at 7.24 p.p.m. for 
1H  and  77.0  p.p.m.  for 
13C  and  relative  to  0.1%  external  acetone  at  2.225  p.p.m.  for 
1H  for 
solutions in D2O.  Electrospray  ionization  mass  spectra  were  recorded  on  a  Micromass  Zabspec  
TOF-mass spectrometer.  
Prop-2-ynyl 2-(2-(2-t-butyloxycarbonylaminoethoxy)ethoxy)ethylcarbamate (1). To a solution 
of  tert-butyl  2-[2-(2-aminoethoxy)ethoxy]ethylcarbamate  [12]  (698  mg,  2.81  mmol)  in  dry  DCM  
(3 mL) at −78 ° C triethylamine (0.85 g, 8.4 mmol) was added followed by propargyl chloroformate 
(522 mg, 4.4 mmol). The mixture was allowed to warm to room temperature and then stirred for 1.5 h. 
The mixture was diluted with DCM, washed with brine, concentrated and chromatographed on silica 
gel using hexane-acetone (7:3) to yield product 1 as a clear syrup (689 mg, 74%); 
1H-NMR (CDCl3)  
ʴ: 5.63 (bs, 1 H, NH), 5.26 (bs, 1 H, NH), 4.93 (d, 2 H, J 2.3 Hz, CH2), 3.88–3.86 (m, 4 H, OCH2), 
3.83–3.76 (m, 4 H, OCH2), 3.66–3.60 (m, 2 H, NCH2), 3.57–3.52 (m, 2 H, NCH2), 2.70 (t, 1 H, CH), 
1.70 (s, 9 H tBu); ESI HRMS: m/z: calcd for C15H26N2O6Na: 353.1683; found: 353.1681 [M + Na]
+. 
3-O-Acetyl-6-O-(10-oxo-3,6,11-trioxa-9-azatetradec-13-ynyl)carbamoyl-4-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-1,2-O-[(S)-1-(methoxycarbonyl)ethylidene]-α-D-glucopyranoside 
(3). Alkyne 1 (545 mg, 1.65 mmol) was dissolved in TFA (1.6 mL) and left at room temperature for  
1  h.  The  mixture  was  concentrated,  treated  with  Et3N  and  concentrated  again  then  
3-O-acetyl-6-O-(4-nitrophenyloxycarbonyl)-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,2-O-
[(S)-1-(methoxycarbonyl) ethylidene]-ʱ-D-glucopyranoside 2 [11] (886 mg, 1.105 mmol) was added. 
The mixture was dissolved in dry DCM (10 mL) and triethylamine (310 μL, 2.21 mmol) was added. 
The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated and 
chromatographed on silica gel using hexane-acetone (2:1 to 1:1) to provide the title compound 3 as a 
white foam (0.93 g, 94%); 
1H-NMR (CDCl3) ʴ: 5.76 (d, 1 H, J1,2 5.13 Hz, H-1) 1.53–1.52 (m, 1 H,  
H-3), 5.46–5.40 (m, 1 H, NH), 5.38 (dd, 1 H, H J3',4' 3.5 Hz, J4',5' 0.7 Hz, H-4'), 5.18 (dd, 1 H, J1',2'  
7.0 Hz, J 2',3' 10.4 Hz, H-2'), 5.01 (dd, 1 H, H-3'), 4.68 (d, 2 H, J 2.2 Hz, CH2), 4.62 (d, 1 H, H-1'), 
4.36–4.33 (m, 1 H, H-2), 4.24 (dd, 1 H, J5,6a 2.2 Hz, J6a,6b 11.7 Hz, H-6a), 4.18–4.10 (m, 3 H, H-6b,  
H-6'a,  H-6'b),  3.96–3.93  (m,  1  H,  H-5'),  3.92–3.88  (m,  1  H,  H-5),  3.76  (s,  3  H,  OCH3),  
3.64–3.54 (m, 8 H, OCH2), 3.42–3.36 (m, 4 H, NCH2), 2.48 (t, 1 H, CH), 2.18, 2.10, 2.03 1.98 (5 s, 15 
H,  5  OAc),  1.76  (s,  3  H,  CH3);  ESI  HRMS:  m/z:  calcd  for  C37H52N2O23Na:  915.2853;  found  Toxins 2011, 3                         
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915.2846 [M + Na]
+. 
1,2-O-[(S)-1-(carboxy)ethylidene]-4-O-(β-D-galactopyranosyl)-6-O-(10-oxo-3,6,11-trioxa-9-
azatetradec-13-ynyl)carbamoyl-α-D-glucopyranoside  (4).  Disaccharide  3  (480  mg,  0.537  mmol) 
was dissolved in dry methanol (4 mL) and 1 M NaOMe (0.54 mL) was added. The solution was stirred 
at room temperature for 16 h. The mixture was concentrated and dissolved in water. After 0.5 h TLC 
indicated that hydrolysis of the methyl ester was complete. The mixture was neutralized with 5 M 
acidic acid and lyophilized to provide the product 4 as white foam (387 mg, 94%). 
1H-NMR (D2O)  
ʴ: 5.62 (d, 1 H, J1,2 5.0 Hz, H-1), 4.67 (d, 1 H, J 2.1 Hz, CH2), 4.44 (d, 1 H, J1',2' 7.8 Hz, H-1'),  
4.41–4.37 (m, 2 H, J2,3 4.1 Hz, J6a,6b 11.9 Hz, H-3, H-6a), 4.24 (dd, 1 H, J5,6b 5.2 Hz, H-6b), 4.18 (dd, 1 
H, H-2), 4.06–4.01 (m, 1 H, H-5), 3.91 (d, 1 H, J3',4' 3.4 Hz, H-4'), 3.82–3.60 (m, 13 H, H-4, H-3', H-5', 
H-6'a, H-6'b, 4 ×  OCH2), 3.55 (dd, 1 H, H-2'), 3.36–3.32 (m, 4 H, 2 ×  NCH2), 2.9 (t, 1 H, CH), 1.64 (s, 
3 H, CH3). ESI HRMS: m/z: calcd for C26H39N2O18: 667.2203; found 667.2205 [M − H]
−. 
1,2-O-[(S)-1-(carboxy)ethylidene]-4-O-[4-O-(α-D-galactopyranosyl)-β-D-galactopyranosyl]-6-
O-(10-oxo-3,6,11-trioxa-9-azatetradec-13-ynyl)carbamoyl-α-D-glucopyranoside  (5).  Compound  4 
(379 mg, 0.537 mmol) was dissolved in water (5.34 mL) and the pH was adjusted to 7.5 by addition of 
solid NaHCO3. Then 1 M HEPES buffer (pH: 8, 3.2 mL) was added followed by 0.4 M DTT solution 
(500 μL) and alkaline phosphatase (1 U/μL, 50 μL, Sigma). UDP-glucose (578 mg, 0.849 mmol) was 
dissolved in the reaction mixture and the fusion enzyme GalT/UDP-4'-epimerase [21] (950 μL) was 
added. The reaction mixture was incubated at 37 ° C. After 24 h the reaction mixture was treated with 
Dowex H
+ resin, filtered and freeze-dried. NMR of the crude product confirmed the reaction was 
complete. The mixture was purified on silica gel using DCM-methanol (2:1 with 2% acetic acid) to 
afford after 2 passages pure trisaccharide 5 (270 mg, 61%). Impure fractions were further purified on 
HPLC (C18) using water (with 0.1% TFA)–acetonitrile to yield an additional amount of trisaccharide 
(51 mg, 11%); 
1H-NMR (D2O) ʴ: 5.64 (d, 1 H, J1,2 5.0 Hz, H-1), 4.94 (d, 1 H, J1'',2'' 4.0 Hz, H-1''), 4.67 
(d, 2 H, J 2.2 Hz, CH2), 4.51 (d, 1 H, J1',2' 7.8 Hz, H-1'), 4.41–4.33 (m, 3 H, H-3, H-6a, H-5''),  
4.28–4.21 (m, 2 H, H-2, H-6b), 4.04–4.00 (m, 3 H, H-5, H-4', H-4''), 3.94–3.90 (m, 2 H, H-6'a, H-3''), 
3.85–3.75 (m, 4 H, H-4, H-5', H-6'b, H-2''), 3.72–3.66 (m, 7 H, H-3', H-6''a, H-6''b, 2  ×  OCH2),  
3.63–3.56 (m, 5 H, H-2', 2 ×  OCH2 ), 3.34–3.32 (m, 4 H, 2 ×  NCH2), 2.90 (t, 1 H, CH), 1.69 (s, 3 H, 
CH3). ESI HRMS: m/z: calcd for C32H50N2O23: 829.2732; found: 829.2734 [M − H]
−. 
(R,S)-5-(3-azido-2-hydroxypropoxy)-N,N,2-trimethyl-1,3-dioxane-2-carboxamide  (7).  Epoxide 
6  [13]  (4.595  g,  18.734  mmol)  was  dissolved  in  dry  DMF  (20  mL)  then  sodium  azide  (3.66  g,  
56.2 mmol) and ammonium chloride (3.01 g, 56.2 mmol) were added and the mixture was stirred for  
5 h at 50  C then overnight at room temperature. Water (100 mL) was added and the mixture was 
extracted with ethyl acetate (3 ×  50 mL). Combined organic layers were washed with saturated NH4Cl 
and brine, then dried with MgSO4, filtered and concentrated. The residue was purified on silica gel 
using hexane-acetone (3:1) to provide the title compound 7 as a clear syrup (2.9 g, 54%). 
1H-NMR 
(CDCl3) ʴ: 4.10–4.06 (m, 2 H, H-4e, H-6e), 3.92-3.82 (m, 1 H, OCH), 3.70–3.48 (m, 5 H, H-4a, H-5,  
H-6a, OCH2), 3.40–3.28 (m, 2 H, NCH2), 3.24 and 3.02 (2s, 6 H, NMe2), 1.52 (s, 3 H, CH3); ESI 
HRMS: m/z: calcd for C11H20N4O5Na: 311.1326; found: 311.1329 [M + Na]
+. 
(R,S)-5-{3-azido-2-[2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyloxy]propoxy}-N,N,2-trimethyl-1,3-dioxane-2-carboxamide  (9).  Azide  7  (1.05  g, 
3.64 mmol) and lactosyl trichloroacetimidate 8 [14] (3.37 g, 4.32 mmol) were dried together under Toxins 2011, 3                         
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vacuum overnight then dissolved in dry DCM (30 mL) and powdered molecular sieves 4 Å were added 
and the mixture was stirred under argon for 0.5 h and cooled to 0 °C . TMSOTf (50 μL, 61 mg,  
0.27  mmol)  was  added  slowly  then  the  ice  bath  was  removed  and  stirring  continued  at  room 
temperature. After 40 min the mixture was neutralized with a drop of Et3N, filtered through celite, 
concentrated and chromatographed on silica gel using hexane-acetone (3:1 to 3:2) to provide the title 
product 9 as white foam (2.4 g, 69 %); 
1H-NMR (CDCl3) ʴ: 5.36–5.34 (m, 1 H, J3',4' 3.4 Hz, H-4'), 
5.20−5.16 (m, 1 H, H-3), 5.13–5.08 (m, 1 H, J1',2' 7.8 Hz, H-2'), 4.98–4.94 (m, 1 H, H-3'), 4.90–4.84 
(m, 1 H, J1,2 7.9 Hz, H-2), 4.63 (d, 1 H, H-1), 4.60–4.56 (m, 1 H, H-6a), 4.52–4.49 (m, 1 H, H-1'), 
4.15–4.02 (m, 5 H, H-4epyr, H-6epyr, H-6b, H-6a', H-6b'), 3.90–3.85 (m, 1 H, H-5'), 3.83–3.68 (m, 2 H, 
H-4, CH), 3.65–3.44 (m, 6 H, H-5, H-4apyr, H-5pyr, H-6apyr, OCH2), 3.41–3.35 and 3.30–3.22 (2 m, 2 
H, NCH2), 3.22 and 3.02 (2 s, 6 H, NMe2), 2.16–1.97 (ms, 21 H, 7 ×  OAc), 1.50 (s, 3 H, CH3). ESI 
HRMS: m/z: calcd for C47H54N4O22Na: 929.3; found: 929.3 [M + Na]
+. 
(R,S)-5-{3-acetamido-2-[2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyloxy]propoxy}-N,N,2-trimethyl-1,3-dioxane-2-carboxamide  (10).  To  a  solution  of 
azide 9 (945 mg, 1.04 mmol) in dry THF (19 mL) triphenylphosphine (423 mg, 1.6 mmol) was added 
and the mixture was stirred at 65 ° C for 6 h then water (2.5 mL) was added and the mixture was stirred 
at 65 ° C for 6.5 h, then concentrated, co-evaporated with toluene and dried under vacuum. The residue 
was dissolved in pyridine (20 mL) and acetic anhydride (10 mL) was added then the mixture was left 
at room temperature overnight. The mixture was concentrated, co-evaporated with toluene and the 
residue  was  chromatographed  on  silica  gel  using  hexane-acetone  (1:1)  to  provide  
N-acetate 10 as a white foam (635 mg; 65 %); 
1H-NMR (CDCl3) ʴ: 6.07 (t, 0.45 H, J 5.5 Hz, NH), 
5.89  (t,  0.55  H,  J  5.5  Hz,  NH),  5.35  (dd,  1  H,  J3',4'  3.4  Hz,  J4',5'  0.3  Hz,  H-4'),  5.18  (dd,  1  H,  
J2,3 = J3.4 = 9.4 Hz, H-3), 5.13–5.10 (m, 1 H, J1',2' 7.9 Hz, J2',3' 10.4 Hz, H-2'), 4.98 (dd, 1 H, H-3'), 
4.88–4.83 (m, 1 H, H-2), 4.63 (d, 0.55 H, H-1), 4.60–4.56 (m, 1 H, H-6a), 4.55 (d, 0.45 H, H-1), 4.50 
(d,  1  H,  H-1'),  4.16–4.02  (m,  5  H,  H-6b,  H-6'a,  H-6'b,  H-4epyr,  H-6epyr),  3.90–3.86  (m,  1  H,  
H-5'), 3.79–3.70 (m, 2 H, H-4, OCH), 3.66–3.41 (m, 7 H, H-5, H-4apyr, H-5pyr, H-6apyr, NCH, OCH2), 
3.22 (s, 3 H, NCH3), 3.21–3.12 (m, 1 H, NCH), 2.17–2.04 (ms, 18 H, 6 x OAc), 1.96 (s, 6 H, NAc, 
OAc), 1.50 (2 s, 3 H, CH3); ESI HRMS: m/z: calcd for C39H58N2O23Na: 945.3323, found: 945.3315 [M 
+ Na]
+.  
(R,S)-5-{3-(prop-2-yn)oxycarbonylamino-2-[4-(β-D-galactopyranosyl)-β-D-glucopyranosyloxy] 
propoxy}-2-methyl-1,3-dioxane-2-carboxylic  acid  (12).  Acetate  10  (186  mg,  0.2  mmol)  was 
dissolved in methanol (4 mL) and transferred to a plastic Falcon tube, then 4 M NaOH (0.5 mL,  
2 mmol) was added. The mixture was stirred at 80 °C . After 3 days the reaction was not complete as 
checked  by  NMR.  More  4  M  NaOH  (0.1  mL,  0.4  mmol)  was  added  and  stirring  was  continued 
overnight at 85 ° C. The mixture containing hydrolysis product 11 was treated with dry ice until the 
solution reached pH 8–9. Then propargyl chloroformate (40 μL, 0.4 mmol) was added and the mixture 
was stirred at room temperature. After 2 h the mixture was purified on HPLC (C-18) using water 
containing  0.1%  TFA—acetonitrile  gradient.  Two  fractions  were  isolated,  concentrated  and  
freeze-dried. First fraction was the product of incomplete hydrolysis of 10 (R,S)-5-{3-acetamido-2- 
[4-(β-D-galactopyranosyl)-β-D-glucopyranosyloxy]propoxy}-2-methyl-1,3-dioxane-2-carboxylic  acid 
(11a) (54 mg, 45%), 
1H-NMR (D2O) ʴ: 4.56 (d, 1 H, J1,2 7.9 Hz, H-1), 4.44 (d, 1 H, J1',2' 7.8 Hz,  
H-1'), 4.16 (dd, Jvic 4.5 Hz, Jgem 11.4 Hz, H-4epyr, H-6epyr), 4.02–3.99 (m, 1 H, CH), 3.95 (dd, 1 H, J5,6a Toxins 2011, 3                         
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1.7 Hz, J6a,6b 12.1 Hz, H-6a), 3.06 (d, 1 H, J3',4' 3.3 Hz, H-4'), 3.82 (m, 14 H, H-3, H-4, H-5, H-6b, H-2', 
H-3', H-5', H-6'a, H-6'b, H-4apyr, H-5pyr, H-6apyr, OCH2), 3.40–3.29 (m, 3 H, H-2, NCH2), 2.00 (s, 3 H, 
OAc), 1.00 (s, 3 H, CH3); ESI HRMS: m/z: calcd for C23H39NO17: 624.211; found: 624.2104 [M + 
Na]
+. This intermediate can be recycled. 
The second fraction was the target compound 12 (59 mg, 46%); 
1H-NMR (D2O) ʴ: 4.65 (bs, 2 H, 
CH2  propargyl),  4.56–4.50  (m,  1  H,  J1.2  7.9  Hz,  H-1),  4.42  (d,  1  H,  J1',2'  7.8  Hz,  H-1'),  4.24–4.16  
(m,  2  H,  H-4epyr,  H-6epyr),  4.00–3.88  (m,  3  H,  J3',4'  3.3  Hz,  H-6a,  H-4',  CH),  3.86–3.50  (m,  
14  H,  J2',3  9.9  Hz,  H-3,  H-4,  H-5,  H-6b,  H-2',  H-3',  H-5',  H-6'a,  H-6'b,  H-4apyr,  H-5pyr,  
H-6apyr, OCH2), 3.30–3.24 (m, 3 H, H-2, NCH2), 2.90 (bs, 1 H, CHpropargyl), 1.52 (s, 3 H, CH3); ESI 
HRMS: m/z: calcd for C25H38NO18: 640.2094; found: 640.2091 [M − H]
−. 
(R,S)-5-{3-(prop-2-yn)oxycarbonylamino-2-[α-D-galactopyranosyl-(1-4)-β-D-galactopyranosyl-
(1-4)-β-D-glucopyranosyloxy]propoxy}-2-methyl-1,3-dioxane-2-carboxylic  acid  (13).  Lactose 
derivative 12 (110 mg, 0.17 mmol) was dissolved in water (1.5 mL) and neutralized with dry NaHCO3. 
Then other components were added in the following order: 1 M HEPES buffer (pH: 8; 0.93 mL), DTT 
solution (0.4 M, 145 μL), alkaline phosphatase (1 U/μL, 14.5 μL, Sigma), UDP-glucose (157 mg, 
0.257  mmol)  and  crude  fusion  enzyme  GalT/UDP-4'-epimerase  [21]  (0.3  mL).  The  mixture  was 
incubated for 40 h at 37 ° C. The mixture was treated with Dowex H
+ resin, filtered and purified on 
HPLC (C-18) using water with 0.1% TFA and acetonitrile gradient. The fraction containing product 
was concentrated and lyophilized to afford the product 13 as a white foam (116 mg, 85 %); 
1H-NMR 
(D2O) ʴ: 4.92 (d, 1 H, J1'',2'' 4.0 Hz, H-1''), 4.66 (d, 2 H, J 1.8 Hz, CH2 propargyl), 4.56–4.52 ( m, 1 H,  
J1,2 7.6 Hz, H-1), 4.50 (d, 1 H, J1',2' 7.8 Hz, H-1'), 4.34–4.31 (m, 1 H, J5'',6''a = J5'',6''b= 6.4 Hz, H-5''), 
4.22 (m, 2 H, H-4epyr, H-6epyr), 4.03–4.00 (m, 2 H, J3',4' 3.2 Hz, J3'',4'' 3.3 Hz, H-4', H-4''), 3.99–3.94 (m, 
2  H,  H-5,  CH),  3.93–3.54  (m,  18  H,  H-3,  H-4,  H-6a,  H-6b,  H-2',  H-3',  H-5',  H-6'a,  
H-6'b, H-2'',H-3'', H-6''a, H-6''b, H-4apyr, H-5pyr, H-6apyr, OCH2), 3.38-3.27 (m, 3 H, H-2, NCH2), 2.89 
(bs, 1 H, CHpropargyl), 1.52 (s, 3 H, CH3); ESI HRMS: m/z: calcd for C31H49NO23Na: 826.2588; found: 
826.2588 [M + Na]
+. 
4-Nitrophenyl  2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethyl  carbonate  (15).  To  a  solution  of  
2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol  14  [15]  (1.953  g,  10.37  mmol)  and  4-nitrophenyl 
chloroformate  (2.51  g,  12.5  mmol)  in  dry  DCM  pyridine  (2  mL)  was  slowly  added  at  room 
temperature. After 30 min the reaction was quenched by addition of methanol, diluted with DCM  
and  washed  with  brine.  The  organic  layer  was  collected,  concentrated  and  the  residue  was 
chromatographed on silica gel using hexane acetone (3:1) to provide 15 as a clear syrup (3.345 g; 
91%); 
1H-NMR (CDCl3) ʴ: 8.30–8.26 and 7.42–7.37 (2 m, 4 H, C6H4), 4.46–4.42 (m, 2 H, CH2OCO), 
4.20 (d, 2 H, J 3.4 Hz, CH2 propargyl), 3.84–3.80 (m, 2H, OCH2), 3.73–3.67 (m, 8 H, 4 ×  CH2), 2.43 (t, 1 
H, CHpropargyl); ESI HRMS: m/z: calcd for C16H19NO8: 376.1003; found: 376.1004 [M + Na]
+. 
(R,S)-5-{2-[β-D-galactopyranosyl-(1-4)-β-D-glucopyranosyloxy]-5-oxo-6,9,12,15-tetraoxa-4-
azaoctadec-17-ynyloxy}-2-methyl-1,3-dioxane-2-carboxylic acid (16). To a solution of 10 (545 mg, 
0.59 mmol) in methanol (12 mL) in a plastic tube NaOH (4 M, 2.25 mL, 9 mmol) was added and the 
mixture was stirred at 80 ° C for 3 days. The mixture was diluted with water and treated with dry ice 
until the solution pH was ~11 at which point a solution of 4-nitrophenylcarbonate 15 (0.6 g, 1.7 mmol) 
in methanol (2 mL) was added. The mixture was stirred overnight at room temperature. The reaction 
was not complete. Et3N (410 μL, 3 mmol) and more 15 (0.3 g, 0.85 mmol) were added and the mixture Toxins 2011, 3                         
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was stirred overnight. The reaction was not complete. The mixture was concentrated and purified by 
HPLC  (C-18)  using  water  with  0.1%  of  TFA  and  acetonitrile  gradient  to  provide  compound  16  
(285 mg; 62%) as a white foam; 
1H-NMR (D2O) ʴ: 4.55–4.54 (m, 1 H, J1,2 7.9 Hz, H-1), 4.43 (d, 1 H, 
J1',2' 7.8 Hz, H-1'), 4.23 (d, 2 H, J 2.4 Hz, CH2propargyl), 4.22–4.15 (m, 4 H, H-4epyr, H-6epyr, CH2OCO), 
3.98–3.92  (m,  2  H,  H-6a,  CH),  3.91  (d,  1  H,  J3',4'  3.4  Hz,  H-4'),  3.81–3.50  (m,  24  H,  
J2',3' 9.9 Hz, H-3, H-4, H-5, H-6b, H-2', H-3', H-5', H-6'a, H-6'b, H-4apyr, H-5pyr, H-6apyr, 6 ×  OCH2), 
3.37–3.26 (m, 3 H, H-2', NCH2), 2.89 (t, 1 H, CH propargyl), 1.50 (s, 3 H ,CH3); ESI HRMS: m/z: 
calcd for C31H51NO21Na: 796.2846; found: 796.2841 [M + Na]
+. 
(R,S)-5-{2-[α-D-galactopyranosyl-(1-4)-β-D-galactopyranosyl-(1-4)-β-D-glucopyranosyloxy]-5-
oxo-6,9,12,15-tetraoxa-4-azaoctadec-17-ynyloxy}-2-methyl-1,3-dioxane-2-carboxylic  acid  (17). 
Lactose derivative 16 (273 mg, 0.35 mmol) was dissolved in water (3 mL) and neutralized with dry 
NaHCO3. Then other components were added in the following order: 1 M HEPES buffer (pH: 8;  
1.86 mL), DTT solution (0.4 M, 300 μL), alkaline phosphatase (1 U/μL, 30 μL, Sigma), UDP-glucose 
(320 mg, 0.52 mmol) and crude fusion enzyme GalT/UDP-4'-epimerase [21] (0.5 mL). The mixture 
was incubated for 24 h at 37 ° C then treated with Dowex H
+ resin, filtered and purified on HPLC  
(C-18) using water with 0.1% TFA and acetonitrile gradient. The fraction containing product was 
concentrated and lyophilized to afford the product 17 as a white foam (272 mg; 82 %); 
1H-NMR (D2O) 
ʴ: 4.94 (m, 1 H, J1'',2'' 4.0 Hz, H-1''), 4.67–4.65 (m, 1 H, J1,2 7.8 Hz, H-1), 4.50 (d, 1 H, J1',2' 7.7 Hz,  
H-1'), 4.36–4.32 (m, 1 H, J 5'',6''a = J5'',6''b = 6.4 Hz, H-5''), 4.24 (d, 2 H, J 2.4 Hz, CH2 propargyl),  
4.22–4.16 (m, 4 H, H-4epyr, H-6epyr, CH2OCO), 4.04–4.01 (m, 2 H, H-4', H-4''), 4.00–3.52 (m, 30 H, 
H-3,  H-4,  H-5,  H-6a,  H-6b,  H-2',  H-3',  H-5',  H-6'a,  H-6'b,  H-2'',  H-3'',  H-6''a,  H-6''b,  
H-4apyr, H-5pyr, H-6apyr, OCH, 6 ×  OCH2), 3.38–3.27 (m, 3 H, H-2, NCH2), 2.58 (t, 1 H, CHpropargyl), 
1.50 (s, CH3); ESI HRMS: m/z: calcd for C37H61NO26Na: 958.3374; found 958.3366 [M + Na]
+. 
N-[3-(tert-Butyloxycarbonylamino)propyl]methacrylamide  (19).  To  a  solution  of  
1,3-diaminopropane (1 mL) in DCM (4 mL) methacrylic acid NHS ester (0.36 g, 1.96 mmol) was 
added. The mixture was stirred at room temperature for 15 min. The mixture was concentrated and the 
residue dissolved in methanol. To the solution di(tert-butoxy)carbonyl oxide (2.5 g, 10 mmol) was 
added followed by triethylamine (3 mL, 25 mmol). After 1 h the mixture was concentrated and the 
residue was chromatographed on silica gel using hexane-ethyl acetate (3:2) to give the title product 19 
(0.2 g, 42%); 
1H-NMR (CDCl3) ʴ: 6.74 (broad s, 1 H, NH), 5.73 (s, 1 H, CH2), 5.31 (s, 1 H, CH2), 4.96  
(broad s, 1 H, NH), 3.35 (dd, 2 H, J 6.2 Hz, NCH2), 3.18 (dd, 2 H, J 5.9 Hz, NCH2), 1.96 (s, 3 H, 
CH3),  1.67–1.58  (m,  2  H,  CH2),  1.43  (s,  9  H,  tBu).  ESI  HRMS:  m/z:  calcd  for  C12H22N2O3Na  
([M + Na]
+): 265.15226; found: 265.15212. 
tert-Butyl 2-(2-((4-nitrophenoxy)carbonyloxy)ethoxy)ethylcarbamate (21). 2-(2-Aminoethoxy)-
ethanol (2.17 g; 20.6 mmol) was dissolved in methanol (10 mL) and di(tert-butoxy)carbonyl oxide 
(6.75 g; 30.9 mmol) was added followed by triethylamine (3.13 g, 30.9 mmol). After 30 min the 
mixture was concentrated and dried overnight under a vacuum provided by an oil pump. The residue 
was dissolved in dry DCM (20 mL) and p-nitrophenyl chloroformate (5.18 g, 25.7 mmol) was added 
followed by pyridine (3.26 g, 41.2 mmol). After 30 min the reaction was quenched by addition of 
methanol, then the mixture was diluted with DCM, washed with brine, concentrated and the residue 
was  chromatographed  on  silica  gel  using  hexane-acetone  (4:1)  to  provide  the  product  as  slightly 
yellow syrup (7.146 g, 94%); 
1H-NMR (CDCl3) ʴ: 8.24 and 7.40 (2 d, 4 H, C6H4), 4.90 (broad s, 1 H, Toxins 2011, 3                         
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NH), 4.43 (ddd, 2 H, J 4.6 Hz, J 2.9 Hz, OCH2), 3.77 (ddd, 2 H, OCH2), 3.58 (t, 2 H, J 5.2 Hz, NCH2 ), 
3.38–3.00 (m, 2 H, NCH2), 1.45 (s, 9 H, t-Bu). ESI HRMS: m/z: calcd for C16H22N2O8Na ([M + Na]
+): 
393.12684; found 393.12652. 
Copolymer of N-(2-hydroxypropyl)methacrylamide with methacrylamide 19 (20). A solution 
of  N-(2-hydroxypropyl)methacrylamide  (502.5  mg,  3.5  mmol)  and  19  (42  mg,  0.174  mmol)  in 
degassed water (7 mL) was ultrasonicated under vacuum. A solution of ammonium persulfate (7 mg in 
70 μL of water) was added to the mixture followed by an aq. solution of cysteamine hydrochloride  
(98 μL; 1 mg/100 μL). The reaction mixture was vortexed and incubated at 50 ° C overnight then 
concentrated and dissolved in treated with TFA (8 mL). After 2 h the mixture was concentrated, the 
residue was  dissolved in water, dialyzed extensively  against deionized water, then  freeze-dried to 
provide a white powder of aminated HPMA polymer 20 (445 mg, 82%); 
1H-NMR (D2O) ʴ: 4.00–3.90 
(broad s, 1 H, CHOH), 3.30–3.00 (m, 2.2 H, CH2N, CH2NH2), 2.00–1.60 (m, 2 H, CH2), 1.60–0.80 (m, 
6.3 H, CH2, CH3). Integration of 
1H-NMR signals indicated ~5% incorporation of propylenediamine.  
2.2. Elongation of Side Chains. Preparation of 22 and 23 
To a solution of the polymer 20 (70 mg) in dry DMF (1 mL) the linker 21 (46 mg, 0.123 mmol) was 
added followed by triethylamine (25 mg, 0.25 mmol). The mixture was stirred overnight then diluted 
with water, dialyzed against deionized water and freeze-dried. The dry product was dissolved in TFA 
(2 mL)  and stirred  at  room  temperature for 30 min. The mixture was diluted with  water (8  mL) 
carefully neutralized with dry sodium carbonate (1.33 g) in small portions. Then the solution was 
dialyzed  against  deionized  water  and  lyophilized  to  give  polymer  22  as  white  powder  (62  mg);  
1H-NMR (D2O) ʴ: 4.5 (bs, 8.3 H, CH2OCO), 3.90 (bs, 100 H, CHOHHPMA), 3.80 (bs, 21.8 H, OCH2), 
3.30–2.95 (m, 230 H, NCH2), 2.20–0.60 (m, 840 H, CH2, CH3).  
Polymer 22 (87 mg, 0.029 mmol) was treated with linker 21 again as described for the synthesis of 
22 to yield polymer 23 as white foam (78 mg); 
1H-NMR (D2O) ʴ: 4.60–4.40 (m, 18.5 H, CH2OCO), 
3.90 (broad s, 100 H, CHOH), 3.35–3.20 (m, 32 H, OCH2), 3.65 (broad s, 11 H, OCH2), 3.40–3.00  
(m, 240 H, NCH2), 2.10–0.60 (m, 844 H, CH2, CH3). 
2.3. Conjugation of Lactose Derivative. Preparation of Polymers 24, 25, and 26 
To a clear solution of polymer 20 (52.5 mg, 0.018 mmol) and activated carbonate 2 [11] (3.7 mg,  
0.046 mmol) in dry DMF (1 mL) triethylamine (9.5 mg, 0.093 mmol) was added and the mixture was 
stirred  at  room  temperature  overnight.  The  reaction  mixture  was  diluted  with  water  and  dialyzed 
against  deionized  water,  then  freeze-dried  to  afford  the  protected  intermediate  as  white  powder  
(67.5 mg). The intermediate was dissolved in dry methanol (2.5 mL) and NaOMe (0.5 M, 0.23 mL) 
was added to the solution. The mixture was stirred at room temperature for 3 h and concentrated. The 
residue was dissolved in water (2 mL) and stirred for 1 h then dialyzed against deionized water and 
lyophilized to provide the product 24 as a white powder (50 mg); 
1H-NMR (D2O) ʴ: 5.64 (d, 1 H,  
J1,2 4.8 Hz, H-1), 4.46 (d, 1 H, J1',2' 7.7 Hz, H-1'), 4.43–4.36 (m, 2 H, H-3, H-6a), 4.30–4.15 (m, 2 H,  
H-2, H-6b), 4.08–4.00 (m, 1 H, H-5), 3.94–3.88 (m, 21 H, J3',4' 2.9 Hz, H-4', CHOH), 3.85–3.68 (m,  
4 H, H-4, H-5', H-6a', H-6b'), 3.64 (dd, 1 H, J2',3' 9.9 Hz, H-3'), 3.56 (dd, 1 H, H-2'), 3.30–3.00 (m,  
41 H, NCH2), 2.20–0.60 (m, 160 H, CH2, CH3). Toxins 2011, 3                         
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Polymer 22 was processed in a similar manner to give conjugate 25 as white powder; 
1H-NMR 
(D2O) ʴ: 5.64 (d, 1 H, J1,2 4.7 Hz, H-1), 4.44 (d, 1 H, J1',2' 7.7 Hz, H-2'), 4.42–4.36(m, 2 H, H-3,  
H-6a), 4.30–4.14 (m, 4 H, H-2, H-6a, OCH2OCO), 4.10–3.60 (m, 34 H, H-4, H-5, H-6a, H-6b, H-3', 
H-4', H-5', H-6a', H-6b', OCH, OCH2), 3.58 (dd, 1-H, J2',3' 9.0 Hz, H-2'), 3.40–3.00 (m, 46 H, NCH2), 
2.10–0.60 (m, 173 H, CH2, CH3).  
Polymer 23 was processed in a similar manner to give conjugate 26 as white powder; 
1H-NMR 
(D2O) ʴ: 5.66 (d,1 H, J1,2 4.3 Hz, H-1), 4.46 (d, 1 H, J1',2' 7.8 Hz, H-1'), 4.44–4.16 (m, 2 H, H-3,  
H-6a), 4.28–4.18 (m, 4H, H-2, H-6b, CH2OCO), 4.06–4.00 (m,1 H, H-5), 4.38–3.62 (m, 31 H, H-4,  
H-3', H-4', H-5', H-6a', H-6b', OCH, OCH2), 3.56 (dd, 1 H, J2',3' 9.8 Hz, H-2'), 3.40–3.00 (m, 40 H, 
NCH2), 2.10–0.80 (m, 140 H, CH2, CH3). 
2.4. Enzymatic Galactosylation of HPMA-Lactose Polymers. Preparation of Trisaccharide Conjugates 
HPMA-n0, HPMA-n1, and HPMA-n2  
Polymer 24 (41.5 mg) was dissolved in water (506 μL) then HEPES buffer (43 μL) was added, 
followed by aq. DTT solution (0.4 M, 10.6 μL) and alkaline phosphatase (1 U/μL, 1.06 μL). UDP-Glc 
(12.6 mg, 0.02 mmol) was added and followed by crude fusion enzyme GalT/UDP-4'-epimerase [21] 
(32  μL)  and  the  mixture  was  incubated  at  37  °C   overnight.  Then  it  was  treated  with  aq.  10% 
trichloroacetic acid (620 μL) and centrifuged. The solution was diluted with water and dialyzed against 
deionized  water.  The  dialyzed  solution  was  filtered  through  Milipore  membrane  (0.45  μm)  and 
lyophilized to give the product as a white powder. 
1H-NMR of the sample indicated the reaction was 
70% complete. Enzymatic reaction was repeated to achieve complete conversion to give HPMA-n0 as 
a white powder (32 mg); 
1H-NMR (D2O) ʴ: 5.68 (bs, 1H, H-1), 4.96 (d, 1 H, J1‖,2'' 3.5 Hz, H-1''), 4.52 
(d, 1H, J1,2 7.6 Hz, H-1), 4.46–4.34 (m, 3 H, H-3, H-5''), 4.28–4.18 (m, 2 H, H-2), 4.08–4.01 (m, 3 H, 
H-5,  H-4',  H-4''),  3.98–3.76  (m,  30  H,  H-6a,  H-6b,  H-5',  H-6a',H-6b',  H-2'',  H-3'',  H-6a'',  H-6b'', 
CHOH), 3.76–3.68 (m, 2H, H-4, H-3'), 3.60 (dd, 1 H, J2',3' 9.7 Hz, H-2'), 3.60–3.00 (m, 50 H, NCH2), 
2.1–0.6 (m, 198 H, CH2, CH3). 
Polymer 25 was processed in a similar manner to give conjugate HPMA-n1 as white powder;  
1H-NMR (D2O) ʴ: 5.64 (bs, 1 H, H-1), 4.96 (d, 1 H, J1'',2'' 3.3 Hz, H-1''), 4.52 (d, 1 H, J1,'2' 7.9 Hz,  
H-1'), 4.44 (m, 3 H, H-3, H-6a, H-5''), 4.30–4.16 (m, 4 H, H-2, H-6b, CH2OCO), 4.04 (bs, 3 H, H-5,  
H-4', H-4''), 4.00–3.62 (m, 32 H, H-4, H-3',H-5', H-6a', H-6b', H-2'', H-3'', H-6a'',H-6b'', CH,CH2), 3.60 
(dd,  1-H,  J2',3'  8.7  Hz,  H-2'),  3.40–3.00  (m,  43  H,  NCH2),  2.10–0.80  (m,  157  H,  
CH2, CH3).  
Polymer 26 was processed in a similar manner to give conjugate HPMA-n2 as white powder;  
1H-NMR (D2O) ʴ: 5.66 (bs, 1H, H-1), 4.95 (d, 1 H, H-1''), 4.52 (d, 1 H, H-1'), 4.22–4.36 (m, 3 H,  
H-3,  H-6a,  H-5''),  4.28–4.16  (m,  4  H,  H-2,  H-6b,  CH2OCO),  4.04  (bs,  3  H,  H-5,  H-4',  H-4''),  
3.98–3.56  (m,  38  H,  H-4,  H-2',  H-3',  H-5',  H-6a',  H-6b',  H-2'',  H-3'',  H-6a'',  H-6b'',  CH,  CH2),  
3.40–3.00 (m, 49 H, NCH2), 2.10–0.80 (m, 175 H, CH2, CH3). 
N-(2-(2-(2-azidoethoxy)ethoxy)ethyl)methacrylamide  (27,  AzMA).  To  a  solution  of  2-(2-(2-
azidoethoxy)ethoxy)ethanamine [16] (3.17 g, 18.2 mmol) in DCM (15 mL) and methacrylic anhydride 
(4.2 g, 1.5 eq) was added followed by Et3N (2 g, ~3 eq) and the mixture was stirred for 30 min. 
Chromatography on the silica gel in hexane—ethyl acetate (up to 70%) gave 27 (2.8 g, 63%). 
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(CDCl3) ʴ: 6.26 (s, 1 H, NH), 5.68–5.67 (m, 1 H, CH2=), 5.32–5.30 (m, 1 H, CH2=), 3.68–3.62 (m,  
6 H, CH2), 3.59 (t, 2 H, J 4.7 Hz, CH2), 3.51 (dd, 2 H, J 5.5 Hz, J 10.8 Hz, CH2), 3.37 (t, 2 H J 4.8 Hz, 
CH2),  1.95  (m,  3  H,  CH3); 
13C-NMR  (CDCl3)  ʴ:  168.408  (C=O),  140.078  (C=CH2),  119.374  
(C=CH2), 70.543 (CH2O), 70.236 (CH2O), 70.057 (CH2O), 69.843 (CH2O), 50.621 (C–N3), 39.333 
(CH2–NH),  18.625  (CH3).  ESI  HRMS:  m/z:  calcd  for  C10H18N4O3Na  ([M  +  Na]
+):  265.1271;  
found 265.1271. 
2.5. Typical RAFT Polymerization of Hydroxypropyl Methacrylamide Monomer 
The  statistical  copolymerization  AzMA  and  2-hydroxylpropyl  methacrylamide  (HPMA)  was 
performed at 70 ° C in the presence of 4-cyanopentanoic acid dithiobenzoate (CTP) and 4,4'-azobis 
(4-cyanovaleric acid) (ACVA) as chain transfer agent and initiator, respectively. In a typical protocol, 
AzMA (0.18 mL, 0.4 mmol) and HPMA (1.1 g, 7.6 mmol) was dissolved in double distilled water 
containing a few drops of HCl (8 mL) followed by the addition of CTP (5 mg, 18 µmol) and ACVA  
(5 mg, 18 µmol) in 2-propanol (2mL) (targeted DPn 422, Targeted molecular weight 61 kDa). The 
mixture was purged with nitrogen for 45 minutes and flask was placed in oil bath for polymerization 
under nitrogen for 24 h. The polymerization was quenched using liquid nitrogen and polymer was 
precipitated in acetone. The molecular weight and molecular weight distributions of copolymers were 
determined using gel permeation chromatography in aqueous media. 
2.6. General Procedure for Preparation of Polymeric Narrow Molecular Weight  
Heterobifunctional Ligands 
An  appropriate  HPMA-AzMa  copolymer  (20–25  mg)  and  monomeric  heterobifunctional  ligand 
(5, 13 or 17, 1.5–2.0 eq) were dissolved in water (1 mL) and neutralized with dry NaHCO3 (to pH: 8), 
then 1 M sodium ascorbate (25 μL) and 0.05 M (50 μL) were added and the solution was left on a 
tumbler for 2 days. The reaction was checked by IR for the presence of azide. When no azido group 
could  be  detected  the  reaction  mixture  was  diluted  with  water  and  extensively  dialyzed  against 
deionized water with the addition of EDTA, then filtered and lyophilized. Product was obtained in the 
form of white powder. 
HPMA-16/5-A;
 1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 7.80–7.50 (m, 24 H, NHHPMA), 5.62 (d, 1 
H, J1,2 4.8 Hz, H-1), 5.20 (bs, 2 H, OCH2), 4.94 (d, 1 H, J1'',2'' 3.9 Hz, H-1''), 4.60–4.53 (m, 2H, NCH2), 
4.52  (d,  1  H,  J1',2'  7.7  Hz,  H-1'),  4.42–4.35  (m,  3  H,  H-3,  H-6a,  H-5''),  4.25–4.20  (m,  1  H,  
H-6b), 4.19–4.16 (m, 1 H, H-2), 4.05–4.00 (m, 3 H, H-5, H-4', H-4''), 3.96–3.56 (m, 51 H, H-4, H-2', 
H-3',  H-5',  H-6'a,  H-2'',  H-3'',  H-6''a,  H-6''b,  4  ×   OCH2,  CHOH  HPMA),  3.40–3.00  (m,  60  H,  
2 ×  NCH2, NCH2 HPMA), 2.00–0.60 (m, 228 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-44/5-A; 
1H-NMR (D2O) ʴ: 8.1 (s, 1 H, CHtriazol), 5.62 (d, 1 H, J1,2 4.9 Hz, H-1), 5.20 (bs, 2 
H, OCH2), 4.94 (d, 1 H, J1'',2'' 3.9 Hz, H-1''), 4.60–4.54 (m, 2H, NCH2), 4.51 (d, 1 H, J1',2' 7.7 Hz, H-1'), 
4.42  (m,  3  H,  H-3,  H-6a,  H-5''),  4.22  (m,  1  H,  H-6b),  4.17  (m,  1  H,  H-2),  4.06–3.99  (m,  3  H,  
H-5,  H-4', H-4''), 3.97–3.86 (m, 20 H, H-6'a, H-3'',CHOH  HPMA), 3.86–3.54 (m, 16 H, H-4, H-2',  
H-3', H-5', H-6'b, H-2'', H-6''a, H-6''b, 4 ×  OCH2), 3.70–3.00 (m, 38 H, 2 ×  NCH2, NCH2  HPMA),  
2.00–0.60 (m, 136 H, CH3, CH2, CH3 HPMA). Toxins 2011, 3                         
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HPMA-35/10-A; 
1H-NMR (D2O) ʴ: 8.06 (s, 1 H, CHtriazol), 5.62 (d, 1 H, J1,2 4.9 Hz, H-1), 5.20 (bs, 
2  H,  OCH2),  4.94  (d,  1  H,  J1'',2''  4.0  Hz,  H-1''),  4.60–4.53  (m,  2H,  NCH2),  4.51  (d,  1  H,  J1',2'  
7.7 Hz, H-1'), 4.42–4.34 (m, 3 H, H-3, H-6a, H-5''), 4.22–4.20 (m, 1 H, H-6b), 4.19–4.16 (m, 1 H, H-
2), 4.04–4.00 (m, 3 H, H-5, H-4', H-4''), 3.96–3.86 (m, 13 H, H-6'a, H-3'',CHOH  HPMA), 3.86–3.54  
(m,  16  H,  H-4,  H-2',  H-3',  H-5',  H-6'b,  H-2'',  H-6''a,  H-6''b,  4  ×   OCH2),  3.90–2.90  (m,  28  H,  
2 ×  NCH2, NCH2 HPMA), 2.00–0.60 (m, 100 H, CH3, CH2, CH3 HPMA). 
HPMA-20/15-A; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 5.62 (d, 1 H, J1,2 4.6 Hz, H-1), 5.20 (bs, 
2  H,  OCH2),  4.95  (d,  1  H,  J1'',2''  3.9  Hz,  H-1''),  4.60–4.53  (m,  2H,  NCH2),  4.52  (d,  1  H,  J1',2'  
7.7 Hz, H-1'), 4.42–4.36 (m, 3 H, H-3, H-6a, H-5''), 4.26–4.20 (m, 1 H, H-6b), 4.19–4.15 (m, 1 H,  
H-2), 4.05–4.01 (m, 3 H, H-5, H-4', H-4''), 3.96–3.86 (m, 12 H, H-6'a, H-3'',CHOH HPMA), 3.86–3.54 
(m,  16  H,  H-4,  H-2',  H-3',  H-5',  H-6'b,  H-2'',  H-6''a,  H-6''b,  4  ×   OCH2),  3.90–3.00  (m,  26  H,  
2 ×  NCH2, NCH2 HPMA), 2.20–0.60 (m, 90 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-37/15-A; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 5.62 (d, 1 H, J1,2 4.8 Hz, H-1), 5.20 (bs, 
2  H,  OCH2),  4.94  (d,  1  H,  J1'',2''  3.9  Hz,  H-1''),  4.60–4.54  (m,  2  H,  NCH2),  4.51  (d,  1  H,  
J1',2' 7.7 Hz, H-1'), 4.42–4.34 (m, 3 H, H-3, H-6a, H-5''), 4.24–4.19 (m, 1 H, H-6b), 4.19–4.16 (m,  
1 H, H-2), 4.04–4.01 (m, 3 H, H-5, H-4', H-4''), 3.96–3.86 (m, 11 H, H-6'a, H-3'',CHOH HPMA), 3.86–
3.54  (m,  16  H,  H-4,  H-2',  H-3',  H-5',  H-6'b,  H-2'',  H-6''a,  H-6''b,  4  ×   OCH2),  3.90–3.00  (m,  
22 H, 2 ×  NCH2, NCH2 HPMA), 2.20–0.60 (m, 80 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-44/5-B; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 5.20 (bs, 2 H, OCH2), 4.94 (d, 1H, J1'',2'' 
3.8  Hz,  H-1''),  4.62–4.47  (m,  4  H,  H-1,  H-1',  NCH2),  4.34  (dd,  1  H,  J5'',6''a  ~  J5'',6''b  ~  6.5  Hz,  
H-5''), 4.12–3.99 (m, 4 H, H-4', H-4'', H-4epyr, H-6epyr), 3.99–3.46 (m, 40 H, H-3, H-4, H-6a, H-6b, H-
2', H-3', H-5', H-6'a, H-6'b, H-2'',H-3'', H-6''a, H-6''b, H-4apyr, H-5pyr, H-6apyr, OCH2, OCH  HPMA), 
3.35–2.96 (m, 45 H, H-2, NCH2 HPMA), 2.00–0.06 (m, 176 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-35/10-B; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 5.20 (bs, 2 H, OCH2), 4.94 (d, 1H, J1'',2'' 
3.8  Hz,  H-1''),  4.63–4.47  (m,  4  H,  H-1,  H-1',  NCH2),  4.34  (dd,  1  H,  J5'',6''a  ~  J5'',6''b  ~  6.4  Hz,  
H-5''), 4.12–4.00 (m, 4 H, H-4', H-4'', H-4epyr, H-6epyr), 3.98–3.46 (m, 41 H, H-3, H-4, H-6a, H-6b,  
H-2', H-3', H-5', H-6'a, H-6'b, H-2'',H-3'', H-6''a, H-6''b, H-4apyr, H-5pyr, H-6apyr, OCH2, OCH HPMA), 
3.35–2.96 (m, 41 H, H-2, NCH2 HPMA), 2.00–0.06 (m, 160 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-44/5-C; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 7.90–7.40 (m, 18 H, NH HPMA), 4.94 (d, 1 
H, J1'',2'' 3.9 Hz, H-1''), 4.59–4.48 (m, 3 H, H-1, H-1', OCH2), 4.34 (dd, 1 H, J5'',6''a ~ J5'',6''b ~ 6.5 Hz,  
H-5''), 4.23–4.16 (m, 2 H, CH2OCO), 4.14–4.06 (m, 2 H, H-4epyr, H-6epyr), 4.04–4.00 (m, 2H, H-4',  
H-4''),  3.98–3.49  (m,  54  H,  H-3,  H-4,  H-5,  H-6a,  H-6b,  H-2',  H-3',  H-5',  H-6'a,  H-6'b,  
H-2'', H-3'', H-6''a, H-6''b, H-4apyr, H-5pyr, H-6apyr, OCH, 6 ×  OCH2, OCHHPMA), 3.47–3.00 (m, 45 H, 
H-2, NCH2, NCH2 HPMA), 2.10–0.60 (m, 176 H, CH3, CH2 HPMA, CH3 HPMA). 
HPMA-35/10-C; 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 7.90–7.40 (m, 13 H, NH HPMA), 4.94 (d, 
1 H, J1'',2'' 3.9 Hz, H-1''), 4.60–4.48 (m, 3 H, H-1, H-1', OCH2), 4.34 (dd, 1 H, J5'',6''a = J5'',6''b= 6.5 Hz,  
H-5''), 4.25–4.17 ( m, 2 H, CH2OCO), 4.14–4.06 (m, 2 H, H-4epyr, H-6epyr), 4.04–4.00 (m, 2 H, H-4', 
H-4''),  4.00–3.48  (m,  46  H,  H-3,  H-4,  H-5,  H-6a,  H-6b,  H-2',  H-3',  H-5',  H-6'a,  H-6'b,  
H-2'', H-3'', H-6''a, H-6''b, H-4apyr, H-5 pyr, H-6apyr, 6 ×  OCH2, OCHHPMA), 3.48–3.00 (m, 37 H, H-2,  
2 ×  NCH2, NCH2 HPMA), 2.10–0.60 (m, 136 H, CH3, CH2 HPMA, CH3 HPMA). Toxins 2011, 3                         
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2.7. Typical RAFT Polymerization of Acrylamide Monomers  
The statistical copolymerization of 3-aminopropyl methacrylamide (APMA) and acrylamide (AA) 
was  performed  at  70  ° C  in  the  presence  of  4-cyanopentanoic  acid  dithiobenzoate  (CTP)  and  4, 
4'-azobis(4-cyanovaleric acid) (ACVA) as chain transfer agent and initiator, respectively. In a typical 
protocol  AA  (2  g,  28  mmol)  and  APMA  (0.25  g,  1.4  mmol)  was  dissolved  in  dimethylsulfoxide 
(DMSO) (10 mL) followed by the addition of CTP (8 mg, 29 µmol) and ACVA (2 mg, 7 µmol) 
(targeted DPn 977, Targeted molecular weight 70 kDa). The mixture was purged with nitrogen for  
45  minutes  and  flask  was  placed  in  oil  bath  for  polymerization  under  nitrogen  for  24  h.  The 
polymerization reaction mixture was quenched using liquid nitrogen and polymer was precipitated in 
acetone. The molecular weight and molecular weight distributions of copolymers were determined 
using aqueous gel permeation chromatography.  
PAA-27/5. Poly[acrylamide-co-(3-aminopropylmethacrylamide hydrochloride)] (M.W.: 27000; 5% 
of amine; 210 mg, 141 μmol) was dissolved in water (2.5 mL) and imidazole-1-sulfonyl azide [17] 
(118 mg, 563 μmol) was added followed by 0.4 M solution of CuSO4/H2O (12.5 μL) and pH of the 
solution was adjusted to 10 by addition of 5 M NaOH (200 μL). The reaction mixture was stirred at 
room temperature for 6 h, then dialyzed, filtered and lyophilized to provide the product as an off white 
powder (177 mg). IR: 2103.0 cm
−1, 
1H-NMR (D2O) ʴ: 3.44–3.35 (m, 2 H, NCH2), 3.32–3.12 (m, 2 H, 
NCH2), 2.38–1.98 (m, 16 H, CH2 linker, CH), 1.84–1.34 (m, 32 H, CH2), 1.2–1.08 (m, 3 H, CH3). 
PAA-72/5. The title product was obtained from poly[acrylamide-co-(3-aminopropylmethacrylamide 
hydrochloride)]  as  described  for  preparation  of  PAA-27/5  (M.W.:  72000;  5%  of  amine;  210  mg,  
141 μmol) as described for PAA-27/5. The title product obtained as off white powder (156 mg). IR:  
2103.9 cm
−1. 
1H-NMR (D2O) ʴ: 3.44–3.34 (m, 2 H, NCH2), 3.30–3.12 (m, 2 H, NCH2), 2.38–1.98 (m, 
16 H, CH2 linker, CH), 1.82–1.34 (m, 34 H, CH2), 1.2–1.08 (m, 3 H, CH3). 
PAA-27/5-A. Azide PAA-27/5 (21.8 mg, 14.3 μmol) and 5 (23.5 mg, 28.3 μmol) were dissolved in 
water (1 mL) and pH adjusted to 8. Then 1 M sodium ascorbate (25 μL) and 0.05 M copper sulfate  
(50 μL). The reaction mixture was left on a tumbler for 2 days. Then it was dialyzed, filtered and  
freeze-dried to afford the polymer PAA-27/5-A as a white powder (35 mg). 
1H-NMR (D2O) ʴ: 8.06 (s, 
1 H, CHtriazol), 5.62 (d, 1 H, J1,2 4.9 Hz, H-1), 5.18 (bs, 2 H, OCH2), 4.94 (d, 1 H, J1'',2'' 3.9 Hz,  
H-1''), 4.51 (d, 1 H, J1',2' 7.8 Hz, H-1'), 4.50–4.35 (m, 5 H, J6a,6b 12.0 Hz, H-3, H-6a, H-5'', NCH2), 4.23 
(dd,  1  H,  J5,6b  5.1  Hz,  H-6b),  4.18  (dd,  1  H,  J2,3  3.9  Hz,  H-2),  4.04–4.01  (m,  3  H,  H-5,  H-4',  
H-4''),  3.94–3.89  (m,  2  H,  H-6'a,  H-3''),  3.85–3.60  (m,  16  H,  H-4,  H-2',  H-3',  H-5',  H-6'b,  H-2'',  
H-6''a, H-6''b, 4 ×  OCH2), 3.34–3.29 (m, 4 H, 2 ×  NCH2), 3.20–3.02 (m, 2 H, NCH2), 2.40–2.00 (m, 
16 H, CH2 , CH PAA), 1.80–1.30 (m, 31 H, CH3, CH2 PAA), 1.20–1.00 (m, 3 H, CH3 MAA). 
PAA-72/5-A. Azide PAA-72/5 (21.6 mg, 14.4 μmol) and 5 (24.3 mg, 29 μmol) were dissolved in 
water  (1  mL)  and  reaction  and  work-up  were  performed  as  described  for  PAA-27/5-A.  The  tile  
PAA-72/5-A was obtained as a white powder (35.3 mg). 
1H-NMR (D2O) ʴ: 8.10 (s, 1 H, CHtriazol), 
5.62 (d, 1 H, J1,2 4.9 Hz, H-1), 5.18 (bs, 2 H, OCH2), 4.94 (d, 1 H, J1'',2'' 3.9 Hz, H-1''), 4.51 (d, 1 H, 
J1',2'  7.7  Hz,  H-1'),  4.49–4.34  (m,  5  H,  J6a,6b  11.8  Hz,  H-3,  H-6a,  H-5'',  NCH2),  4.23  (dd,  1  H,  
J5,6b 5.1 Hz, H-6b), 4.18 (dd, 1 H, J2,3 4.0 Hz, H-2), 4.05–4.00 (m, 3 H, H-5, H-4', H-4''), 3.94–3.89 (m, 
2  H,  H-6'a,  H-3''),  3.85–3.60  (m,  16  H,  H-4,  H-2',  H-3',  H-5',  H-6'b,  H-2'',  H-6''a,  H-6''b,  Toxins 2011, 3                         
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4 ×  OCH2), 3.34–3.28 (m, 4 H, 2 ×  NCH2), 3.20–3.02 (m, 2 H, NCH2), 2.40–1.90 (m,19 H, CH2,  
CH PAA), 1.80–1.30 (m, 36 H, CH3, CH2 PAA), 1.20–1.00 (m, 3 H, CH3 MAA). 
2.8. Biological Evaluation 
The  solid-phase  binding-inhibition  and  Vero  cell  cytotoxicity-neutralization  assays  are  fully 
described in previous reports [11,18,19]. In brief, C57BL/6-Tg(APSC)1Imeg transgenic mice [20], 
which exhibit liver-specific expression of human SAP at a stable circulating serum concentration of 
30–40  μg/mL,  were  used  in  the  Stx1-mediated  Shigatoxemia  experiments.  All  experiments  were 
conducted  in  a  double-blind,  placebo-controlled  manner.  All  animal  protocols  were  reviewed  and 
approved (Protocol  Number MO4002) by the  Faculty of Medicine, University of  Calgary Animal 
Welfare  Committee  and  were  performed  according  to  the  Guidelines  published  by  the  Canadian 
Council on Animal Care, (Vol. 1, 2nd ed.). Human SAP-tg mice (n = 4–6 animals per group) were 
intravenously injected with a lethal dose(LD100 20 ng/g of body weight) of Stx1 that was premixed in a 
total volume of 100 μL with a heterobifunctional inhibitor in physiological saline solution. Forty-eight 
h after challenge, the mice were monitored every 4 h and immediately euthanized by CO2 asphyxia if 
signs  of  Shigatoxemia  (lethargy)  became  apparent.  On  the  10th  day,  all  surviving  mice  
were euthanized. 
3. Results and Discussion 
3.1. Synthesis of Heterobivalent Polymers 
Reaction  of  the  p-nitrophenylcarbonate  derivative  of  lactose  2  [11]  with  amine  derived  from  
Boc-protected linker 1 provided protected lactose intermediate 3 with a linker armed with a terminal 
alkyne residue. After deprotection and subsequent enzymatic glycosylation of 4 the heterobifuntional 
ligand 5 was obtained (Scheme 1). 
Scheme 1. Synthesis of the Type A pendant ligand 5. 
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The synthesis of two other heterobifunctional ligands 13 and 17 started with opening of the oxirane 
ring  in  cyclic  pyruvate  derivative  6  with  sodium  azide  (Scheme  2).  The  resulting  alcohol  7  was Toxins 2011, 3                         
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glycosylated with lactose donor 8. Reduction of azide 9 followed by acetylation gave 10, which was  
N and O-deacetylated with NaOH solution to give amine 11. Acylation of the amino group in 11 with 
propargyl chloroformate gave carbamate derivative 12, which was enzymatically ʱ-galactosylated to 
give the desired ligand 13 ready for conjugation to a polymer. The enzymatic synthesis was previously 
described  and  employs  a  fusion  protein  that  incorporates  gluco-galacto  epimerase  and  
ʱ-1,4-galactosyltransferase activities. This allows the use of the relatively cheap UDP-glucose donor to 
achieve the introduction of the terminal ʱ-galactopyranosyl residue. Analogously, ligand 17 with a 
longer  linker  was  obtained  by  first  acylating  11  with  activated  carbonate  15  then  enzymatically 
processing the disaccharide with attached tether 16 to give 17. 
Scheme 2. Synthesis of the Type B pendant ligands 13 and 17. 
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The first set of polymeric ligands was obtained by sequential elongation of the side chain linker in a 
single  batch  of  co-polymer  between  N-(2-hydroxypropyl)  methacrylamide  (18,  HPMA)  and  
N-(3-tert-butoxycarbonylaminoxypropyl)  methacrylamide  (19)  with  cysteamine  hydrochloride  as  a 
radical initiator. After deprotection of the product of polymerization, the HPMA polymer 20 randomly 
decorated with amino groups reacted with linker 21 to provide after deprotection polymer 22 with 
elongated side chains. The procedure was repeated to afford polymer 23 with twice elongated side 
chains (Scheme 3). The heterobifunctional pendant ligand was installed into the three homologous 
polymeric scaffolds 20, 21 and 22 in two steps: first, amino groups in each polymer were coupled with 
the lactose pyruvate derivative 2 to provide after deacetylation the respective polymers 24, 25 and 26, 
each of which were enzymatically galactosylated to provide final products HPMA-n0, HPMA-n1 and 
HPMA-n2 correspondingly.  
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Scheme 3. Synthesis of HPMA conjugates (Type A) by sequential extension of the linker-arm. 
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In  order  to  assess  influence  of polymer  size  on the  activity  of  heterobifunctional  ligands the 
synthesis  of  polymeric  scaffolds  with  randomly  incorporated  azide  functionality  and  different 
molecular  weight  was  performed  by  the  reversible  addition -fragmentation  chain  transfer  process 
(RAFT).  The  RAFT  copolymerization  of  HPMA  with azide  containing methacrylamide  monomer 
(AzMA) was performed in aqueous conditions using 4,4 '-azobis(4-cyanovaleric acid) as the initiator 
and  4-cyanopentanoic  acid  4-dithiobenzoate  as  the  chain  transfer  agent  (Sc heme  4,  Table  1).  Two 
polyacrylamide  analogs PAA-27/5 PAA-72/5 with defined molecular weight were obtained by co-
polymerization  of  acrylamide  with  3-aminopropylmethacrylamide  hydrochloride  followed  by 
azidination of amino group side chains using azidotransfer reagent, imidazole-1-sulfonyl azide [17].  
The conjugation of the heterobifunctional ligands 5, 13 and 17 to the azide-presenting scaffolds was 
accomplished  via  an  efficient  click  reaction  providing  an  array  of  polymeric  heterobifunctional 
ligands:  HPMA-16/5-A,  HPMA-44/5-A,  HPMA-35/10-A,  HPMA-20/15-A,  HPMA-37/15-A, 
HPMA-44/5-B, HPMA-35/10-B, HPMA-44/5-C, and HPMA-35/10-C, PAA-27/5-A, PAA-72/5-A. Toxins 2011, 3                         
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Scheme 4. Synthesis of HPMA conjugates (Types A, B and C) with narrow molecular 
weight distribution by RAFT polymerization. 
HN
HO
O
RAFT
polymerization
O N
H
O
O
O
H
N
O
OH
HO
O OH
O O
OO
HO
O
O
HO
HO
HO OH
COOH
O O
O
O
HO
O
OH
HO
O OH
O
O
OH
O HO
OH
O
HO
HO
HO OH
HN
O
O
O
O
O O
O
O
HO
O
OH
HO
O OH
O O
OH
O HO
OH
O
HO
HO
HO OH
HN
O
R =
R =
R =
HPMA series of conjugates
A
B C
HN
N3
O
27
(AzMA)
O
2
HN O HN O HN O
HO HO HO
HN O
HO
HN O
HO
HN O
HO
HN O
HO
O
HN
O 2
HN O HN O HN O
HO HO HO
HN O
HO
HN O
HO
HN O
HO
HN O
HO
O
HN
N3
O 2
N R O
N N
18
(HPMA) O R
 
Table 1. Polymeric scaffolds obtained by RAFT polymerization. 
Polymer 
a  Molecular Weight, Da  Mw/Mn   AzMA substitution, %  
HPMA-16/5  15900  1.34  5 
HPMA-44/5  43600  1.35  5 
HPMA-35/10  35100  1.34  10 
HPMA-20/15  19500  1.32  15 
HPMA-37/15  36700  1.41  15 
PAA-27/5  27000  1.29  5 
PAA-72/5  72000  1.38  5 
a polymers are named according to the principle monomer; the indices indicate molecular weight in kDa and 
% substitution with azide monomer AzMA.  Toxins 2011, 3                         
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Scheme  5.  Synthesis  of  PAA  conjugates  (Type  A)  with  narrow  molecular  weight 
distribution by RAFT polymerization. 
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3.2. Evaluation of Inhibitory Activity 
Supramolecular inhibition is a novel strategy for the design of antagonists for pathogenic agents. 
The approach takes advantage of an endogenous protein such as an antibody or serum proteins of the 
innate immune system that serve as a template for presentation of a binding moiety specific to the 
target protein or cell [22–26]. In addition to providing a pre-organized scaffold and enhancing activity 
due to the multivalency effect the templating protein can function as an effector which initiates attack 
by  the  immune  system  or  redirects  the  bound  species  away  from  susceptible  organs.  Thus,  
PolyBAIT-mediated interaction with SAP results in re-routing of Stx1 from kidney to the spleen and 
liver, where the toxin can be safely disposed [11].  
In  order  to  address  the  feasibility  of  using  polymeric  heterobifunctional  inhibitors  such  as 
PolyBAIT as injectable drugs to treat patients infected with enterohemorrhagic E. coli two main issues 
have  to  be  resolved,  namely,  replacing  polyacrylamide  with  a  more  biocompatible  polymer,  and 
controlling the molecular weight of the polymer-carrier to be below the kidney excretion cut-off. As 
the  polyacrylamide  backbone  replacement  we  chose  N-(2-hydroxypropyl)methacryamide  (HPMA). 
Since its original use as a blood plasma expander [27,28]. HPMA is the most extensively studied 
soluble polymer with a nondegradable backbone, which itself or as a copolymer have been employed 
in  a  broad  variety  of  biomedical  applications  ranging  from  immunosuppressives,  vaccines, 
cancerostatic drugs, imaging agents and targeting of gene delivery vectors [29].  
Preliminary  evaluation  of  the  feasibility  of  replacing  acrylamide  as  the  polymeric  backbone  in 
PolyBAITs was performed on a series of homologous polymeric inhibitors HPMA-n0, HPMA-n1 and 
HPMA-n2. These differed only in the length of the spacer-arm and were identical in all other respects 
since all of them were prepared from the same batch of aminated polyHPMA by sequential elongation 
of the linker. Inhibition data for both solid phase assay and cell intoxication assay presented in Figure Toxins 2011, 3                         
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2A and Figure 2B revealed a trend of increasing activity with elongation of the spacer. Additionally, 
direct correspondence between activities in both assays was in sharp contrast with other multivalent 
inhibitors, for which we previously observed significant reduction of activity upon transition from 
ELISA to cytotoxicity assays. At the same time, the inhibitory power of the highest activity conjugate 
HPMA-n2  was  still  an  order  of  magnitude  lower  than  that  of  original  polyacrylamide-based  
PolyBAIT (Table 2).  
Conjugate HPMA-n2 was tested in vivo for its ability to prevent intoxication of transgenic mice, 
which express human SAP at levels similar to humans (~20–60 mg/L). At the concentration, which 
was sufficient for the original PolyBAIT preparation to completely protect mice from the effects of 
Stx1 (200 μg/mouse), administration of HPMA-n2 resulted in 10–20 h delay of symptom onset, while 
complete protection was achieved at a 3 fold higher dose (Figure 2C). Again, lower inhibitory activity 
in the solid-phase and cytotoxicity assays directly translated into reduced efficacy in vivo (compare 
original  PolyBAIT  and  HPMA-n2).  This  result  confirmed  the  human  SAP-dependant  protective 
properties of tailored heterobifunctional polymers and the feasibility of transition of the methodology 
to  a  different  polymer-carrier.  Influences  of  length  of  the  linker  on  the  activity  of  the 
heterobifunctional polymer both in ELISA and cell culture assays suggest greater interference of the 
scaffold in HPMA polymers with formation of a supramolecular complex as compared with less bulky 
side chains in polyacrylamide. However, the question of how the nature of the polymer-carrier and its 
variable  parameters  such  as  molecular  weight  and  payload  influence  the  activity  remained  to  
be addressed. 
Reversible  addition–fragmentation  chain  transfer  (RAFT)  polymerization  have  previously  been 
successfully employed to prepare HPMA copolymers with polydispersity of 1.1–1.8 (depending on 
molecular weight) containing methacrylamide monomers with a reactive group or cargo drug [30–32]. 
Such well defined copolymers with a narrow molecular weight range are the best candidates for in vivo 
and clinical testing of polymeric therapeutical and diagnostic agents. In the present work, we took 
advantage of the highly efficient ―click reaction‖, which enables conjugation of the active component 
to a polymer in aqueous media. The azido group of the AzMA monomer incorporated into HPMA 
backbone  served  as  a  reactive  functionality,  which  permited  nearly  quantitative  conjugation  of 
carbohydrate ligands.  
Evaluation of a series of defined molecular weight heterobifunctional inhibitors was conducted in 
solid-phase ELISA assay (Table 2). Surprisingly, with the exception of polymer HPMA-16/5-A with 
the lowest molecular weight, all compounds of the HPMA series have shown very similar activities 
regardless  of  molecular  weight  and  also  regardless  of  the  payload  (percent  incorporation)  of  the 
binding  fragments.  Furthermore,  in  the  case  of  ligands  containing  spatially  separated  binding 
fragments in each pendant grouping (polymers of types B and C Scheme 4), elongation of the linker 
did  not  influence  activity  at  all  in  sharp  contrast  with  the  fused  analogs  as  discussed  above. 
Noteworthy, in both HMPA and polyacrylamide series, increase of effective concentration of pendant 
heterobifunctional ligand either by increasing payload or size of the polymer was counterproductive: 
even if the effective dose remained the same the activity per pendant ligand reduced with increase  
of  size  and  payload.  The  optimal  activity  could  be  achieved  at  relatively  low  payload  and  
incorporation degree. Toxins 2011, 3                         
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Figure  2.  Biological  evaluation  of  HPMA-based  heterobifunctional  inhibitors  of  Stx1. 
Panel  A:  inhibition  of  Stx1  binding  to  Gb3  analog-coated  microtiter  plates;  Panel  B: 
inhibition of intoxication of Vero cells with Stx1 (LD100 25 ng/mL); Panel C: protection of 
from  intoxication  with  Stx1  at  LD100.  Survival  plot  demonstrating  the  efficacy  of  
HPMA-n2 compared with the original PolyBAIT in preventing Stx1-mediated lethality in 
human  SAP-transgenic  mice.  Mice  received  a  single  anterior  dorsal  injection  of  a 
lethal dose  of  Stx1  (LD100  20  ng/g  of  body  weight)  that  was  premixed  with  a  
heterobifunctional inhibitor. 
 
The  crystal  structure  of  Stx1  in  complex  with  P
k-trisaccharide  [33]  revealed  three  distinct  
P
k-trisaccharide  binding  sites  per  B-subunit,  of  which  site  2  has  been  shown  to  have  the  highest  
affinity [34]. Glucose moieties at the reducing end of bound P
k-trisaccharides for site 1 and site 2 are 
located  at  approximately  the  same  distance  from  the  center  pore  of  the  B-pentamer  and  both  are 
sufficient to span the distance between center pore of SAP and bound pyruvate ligand. However, when 
pyruvate is fused to glucose moiety (pendant ligand type A), only binding to site 2 provides the correct 
presentation  of  the  pyruvate  moiety  to  SAP.  Site  3  is  located  too  close  the  center  pore  and  a 
heterobifunctional ligand would be unable to engage both proteins simultaneously at more than one or 
two points. Correct presentation of P
k-trisaccharide as a part of Gb3 glycolipid has recently been shown 
to play an important role in the interaction of Stx1 with the cell surface [35]. Hence, only binding at 
site 2 was considered in our design of pendant heterobifunctional ligands. A molecular model of the 
ternary complex mediated by a fused version of the heterobifunctional ligand (Figure 1) suggests that 
the exact alignment and orientation of each binding fragment to its respective protein should result in 
very  close  protein-to-protein  contact  leaving  no  space  for  a  linker  or  polymeric  scaffold.  It  is, Toxins 2011, 3                         
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therefore, unlikely that the scaffolding polymer and the linker occupy the space between Stx and SAP. 
Furthermore, when the trisaccharide is bound to Stx, the pyruvate moiety is now presented ~1.5–2 Å 
further toward the periphery and not exactly in register with the pyruvate-binding site on the SAP 
surface.  Assembly  of  the  ternary  complex  may  require  conformational  distortions  in  the  separate 
heterobifunctional ligands and entail entropic penalties. As a trade-off, the small gap between the 
multimeric receptors introduced by the short spacer in polymers of types B and C brings about easier 
passage of the scaffolding polymer between proteins and increases the number of possible microscopic 
complexes. Such additional freedom can add a favorable combinatorial entropy term to the binding 
free  energy  [36].  The  optimum  length  of  the  spacer  can  probably  be  found  for  a  particular 
supramolecular assembly. 
Table 2. Activities of PolyBAITs. 
Polymer  Pendant Ligand Type  Linker  Payload, %  IC50, g/mL  IC50, M 
a 
HPMA-n0 
b  Fused  Short  5  3.7  1.07 
HPMA-n1  Fused  Long  5  0.98  0.27 
HPMA-n2  Fused  Extra long  5  0.45  0.12 
HPMA-16/5-A 
c  Fused  Long  5  1.2  0.32 
HPMA-44/5-A  Fused  Long  5  0.22  0.06 
HPMA-35/10-A  Fused  Long  10  0.25  0.11 
HPMA-20/15-A  Fused  Long  15  0.24  0.13 
HPMA-37/15-A  Fused  Long  15  0.19  0.106 
HPMA-44/5-B  Separate  Short  5  0.35  0.095 
HPMA-35/10-B  Separate  Short  10  0.29  0.13 
HPMA-44/5-C  Separate  Long  5  0.27  0.07 
HPMA-35/10-C  Separate  Long  10  0.28  0.12 
PAA-27/5-A  Fused  Long  5  0.019  0.008 
PAA-72/5-A  Fused  Long  5  0.046  0.019 
a based on pendant ligand; 
b this and the following polymers are named according to the principle monomer 
followed by the number of extension linkers holding pendant ligand; 
c this and the following polymers are 
named according to  the principle monomer; indices show  molecular  weight in kDa, % substitution  with 
pendant ligands and type of conjugated unimeric ligand.  
4. Conclusions 
In summary, we have synthesized and evaluated a series of HPMA-based PolyBAITs, polymeric 
heterobifunctional  ligands  that  inhibit  Stx1  in  a  SAP-dependent  manner.  We  observed  that  the 
inhibitory  power  of  PolyBAITs  in  a  solid-phase  assay  correlates  with  the  cytotoxicity  assay  and 
efficacy in vivo. We demonstrate that the inhibition is moderately influenced by the structure of the 
pendant ligand and the length of the spacer but is practically independent of molecular weight and the 
polymer density of the glycans. Our results suggest that steric bulk of the side chains in the polymeric 
scaffold  impedes  assembly  of  a  supramolecular  complex  with  endogenous  serum  protein  SAP  
and  requires  heterobifunctional  ligands  that  allow  for  greater  separation  between  specific  
binding fragments.  Toxins 2011, 3                         
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